That "low-normal" range can be misleading because whats technically normal doesnt always
Ive had patients come in expecting MOTS-C to make them lean while they eat fast food five times a week
It was developed by Eli Lilly and entered the published Phase 2 program in 2023 with three parallel disease contexts: obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease
They are not independently verified by this publication, may not represent typical outcomes, and should not be interpreted as guarantees of weight loss, medication eligibility, side-effect profile, prescription approval, or health outcomes
GLP-1 Receptor Agonists: Medications and Their Benefits Several GLP-1 receptor agonists are available as medications, primarily used to treat type 2 diabetes
Circulating resistin levels in relation with insulin resistance, inflammatory and endothelial dysfunction markers in patients with type 2 diabetes and impaired fasting glucose